lenacapavir

Lenacapavir, sold under the brand names Sunlenca among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is taken by mouth or by subcutaneous injection. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor.
The most common side effects include reactions at the injection site and nausea.
Lenacapavir was approved for medical treatment in the European Union in August 2022, in Canada in November 2022, and in the United States in December 2022. It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration for treating HIV/AIDS. In June 2025, lenacapavir, as Yeztugo, received approval in the US for HIV prevention.

View More On Wikipedia.org
Recent contents
  1. Eronda

    Lenacapavir Demand Outstrips Supply in Uganda

    The ministry of Health says demand for Lenacapavir, the newly introduced twice-yearly HIV prevention injection, has exceeded available supplies as increasing numbers of people, particularly men, seek access to the drug. At the launch of the programme in April, the ministry announced that 19,200...
  2. Eronda

    Uganda set to launch Lenacapavir Injectable PrEp at Lira Regional Referral Hospital

    Uganda is taking a giant leap towards an HIV-free generation. This Friday, the country will launch Lenacapavir, a long-acting injectable drug for HIV prevention, administered twice yearly. The launch event will take place at Lira Regional Referral Hospital by the Minister of health Jane Ruth...
  3. Waufukweni

    Rwanda yapata Ufadhili mpya wa kuzuia UKIMWI

    Rwanda na mataifa mengine 11 yatanufaika na ufadhili mpya wa Marekani kwa ajili ya dawa ya kuzuia maambukizi ya virusi vya UKIMWI. Kupitia ushirikiano wa Marekani na shirika la Global Fund zaidi ya watu wengine milioni moja duniani watapatiwa dawa hiyo iitwayo Lenacapavir. Hapo kabla...

Our Community

Coming Soon

Regional Communities

Coming Soon
Back
Top Bottom
Menu
Forums
New posts
Log in
Register